Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

US Pharmaceuticals Ishares ETF (NY: IHE )

69.24 +0.00 (+0.01%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about US Pharmaceuticals Ishares ETF

FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency. 
Via Benzinga
Topics Government
Exposures Political Product Safety
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease. 
Via Benzinga
Topics Government
Exposures Political
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
Via Talk Markets
Topics ETFs
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
3 Sector ETFs That Beat The Market Last Week
Here are three ETFs from different sectors that were in green last week. 
Via Talk Markets
Topics ETFs
US Pharmaceuticals: A Bifurcated Market
The US pharmaceutical industry faces two important goals that conflict with each other. 
Via Talk Markets
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline. 
Via Benzinga
Topics Stocks
Exposures US Equities
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge
Bank of America lists 10 market surprises; warns investors to be wary of the bond market's dovish position compared to the Fed. 
Via Benzinga
Topics Bonds
Exposures Debt Markets
3 Beaten-Down ETFs To Buy For A Turnaround In 2024
Following three consecutive monthly losses since the COVID pandemic began in March 2020, Wall Street recorded a robust recovery starting in November. we have highlighted ETFs from different zones that... 
Via Talk Markets
Topics ETFs
Exposures COVID-19
5 Secret Santa ETFs That Might Surprise You This Christmas
Wall Street has been sizzling hot this holiday season. This is likely to continue, given that the Santa Claus rally is on the way. Against such a backdrop, there are some hidden gems which could... 
Via Talk Markets
Topics ETFs
Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest
In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) raised their voices by calling out sick or walking out... 
Via Benzinga
5 Sector ETFs That Outperformed in Turbulent August
Wall Street has lost momentum since the start of August, triggered by the series of bank downgrades and fears of higher rates for a longer-than-expected period. 
Via Talk Markets
Topics ETFs
Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
While longer-than-expected rate worries and banking concerns led to feeble trading in recent weeks, a few equity ETFs rose or saw a modest decline over the past month. 
Via Talk Markets
Topics ETFs
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
3 Biotech Stocks to Sell in June Before They Crash and Burn
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them. 
Via InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
4 Sector ETFs To Watch Ahead Of Mid-Election Results
Some market analysts are signaling that a political gridlock by Republicans may be a positive for Wall Street and the U.S. economy. 
Via Talk Markets
5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority?
The 2022 election was held on Tuesday, Nov. 8. No decision has been made as to who won many of the key battles, including several pivotal seats in the U.S. House of Representatives and U.S. Senate. 
Via Benzinga
Pharma ETFs In Focus Post Q3 Earnings
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
ETF Mid-Year Outlook & Investing Strategies
While positioning the portfolio for the second half investors should focus on three themes: 1) embracing volatility, 2) living with inflation, and 3) the long-term impacts of shortages. 
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
Via Talk Markets
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
Johnson & Johnson has again announced positive data highlighting the efficiency of its single-shot COVID-19 vaccine in providing protection against COVID-related hospitalizations. 
Via Talk Markets
Exposures COVID-19
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
Investors have one more reason to cheer the COVID-19 vaccine update as the FDA has approved emergency use of a booster dose of the Pfizer Inc. and BioNTech SE COVID-19 vaccine. 
Via Talk Markets
Exposures COVID-19 Product Safety
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Tuesday Talk: Slip Sliding Sideways
With the Middle East seemingly going to Hell in a proverbial handbasket the markets seem to be slip sliding, not away (as the Paul Simon song would have it) sideways as it were. 
Via Talk Markets
5 Sector ETFs That Survived Last Week's Turmoil
Here are five sector ETFs that performed well last week and survived the broad market rout. 
Via Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.